All Stories

  1. Development and Validation of Methodologies for the Identification of Specialized Pro-Resolving Lipid Mediators and Classic Eicosanoids in Biological Matrices
  2. The endocannabinoid anandamide activates pro‐resolving pathways in human primary macrophages by engaging both CB2 and GPR18 receptors
  3. LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and associates with viral infections
  4. Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors
  5. Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease
  6. Efferocyte‐Derived MCTRs Metabolically Prime Macrophages for Continual Efferocytosis via Rac1‐Mediated Activation of Glycolysis
  7. Reply to: Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples
  8. Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice
  9. Author Correction: A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae
  10. Mistakes in the re-analysis of lipidomic data obtained from a human model of resolving inflammation lead to erroneous conclusions
  11. Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention
  12. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis
  13. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation
  14. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans
  15. Deletion of macrophage Gpr101 disrupts their phenotype and function dysregulating host immune responses in sterile and infectious inflammation
  16. Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension
  17. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
  18. Vagus nerve stimulation promotes resolution of inflammation by a mechanism that involves Alox15 and requires the α7nAChR subunit
  19. Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
  20. MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis
  21. Evidence for the presence and diagnostic utility of SPM in human peripheral blood
  22. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions
  23. Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease
  24. Lipid mediator n‐3 docosapentaenoic acid‐derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G‐protein‐coupled receptor
  25. 20‐hydroxyeicosatetraenoic acid (20‐HETE) is a pivotal endogenous ligand for TRPV1‐mediated neurogenic inflammation in the skin
  26. Aspirin activates resolution pathways to reprogram T cell and macrophage responses in colitis-associated colorectal cancer
  27. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis
  28. Stereoselective Synthesis, Configurational Assignment and Biological Evaluations of the Lipid Mediator RvD2 n‐3 DPA
  29. Differential Lipid Mediator Involvement in the Different Forms of Genetic Frontotemporal Dementia: Novel Insights into Neuroinflammation
  30. Lipid Mediator n-3 Docosapentaenoic Acid-Derived Protectin D1­(PD1n-3DPA) Enhances Synaptic Inhibition of Hippocampal Principal Neurons by Interaction with a G-Protein Coupled Receptor
  31. Dysregulated Maresin Concentrations in Plasma and Nasal Secretions From Patients With Chronic Rhinosinusitis
  32. Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients
  33. Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19
  34. Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis
  35. Loss of 15-lipoxygenase disrupts Treg differentiation altering their pro-resolving functions
  36. 14,17,18-Trihydroxy-Eicosatetraenoic Acid: A Novel Pro-Resolving Lipid Mediator from Marine Microalgae
  37. Platelets orchestrate the resolution of pulmonary inflammation in mice by T reg cell repositioning and macrophage education
  38. Changes in brown adipose tissue lipid mediator signatures with aging, obesity, and DHA supplementation in female mice
  39. Splenic Nerve Neuromodulation Reduces Inflammation and Promotes Resolution in Chronically Implanted Pigs
  40. Protective activities of distinct omega-3 enriched oils are linked to their ability to upregulate specialized pro-resolving mediators
  41. HIF1α activation in dendritic cells under sterile conditions promotes an anti-inflammatory phenotype through accumulation of intracellular lipids
  42. Methodologies and Procedures Employed in the Identification and Quantitation of Lipid Mediators via LC-MS/MS
  43. Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
  44. The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance During E. coli Infections
  45. Editorial: Role of Blood Cells in Inflammatory and Vascular Disorders
  46. RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance
  47. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease
  48. ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins
  49. Imbalance of proresolving lipid mediators in persistent allodynia dissociated from signs of clinical arthritis
  50. Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality
  51. A combination of LCPUFA ameliorates airway inflammation in asthmatic mice by promoting pro-resolving effects and reducing adverse effects of EPA
  52. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes
  53. Enzymatic studies with 3-oxa n-3 DPA
  54. Plant‐ and Fish‐Derived n‐3 PUFAs Suppress Citrobacter Rodentium –Induced Colonic Inflammation
  55. Stereoselective synthesis of MaR2n-3 DPA
  56. Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway
  57. Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses
  58. A Single Injection of Docosahexaenoic Acid Induces a Pro-Resolving Lipid Mediator Profile in the Injured Tissue and a Long-Lasting Reduction in Neurological Deficit after Traumatic Brain Injury in Mice
  59. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections
  60. Addendum: Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1 n −3 DPA
  61. Proresolving Mediators LXB4 and RvE1 Regulate Inflammation in Stromal Cells from Patients with Shoulder Tendon Tears
  62. Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis
  63. Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells
  64. Synthesis, Structural Confirmation, and Biosynthesis of 22-OH-PD1n-3 DPA
  65. Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
  66. Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules
  67. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
  68. 15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
  69. Tendon cells isolated from patients with persistent shoulder tendinopathy show dysregulated resolution responses
  70. Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock
  71. Pro-Resolving Mediator Profiles And 5-Lipoxygenase Activity In Cerebrospinal Fluid Correlate with Disease Severity and Outcome in Adults with Tuberculous Meningitis
  72. Proresolving mediators LXB4 and RvE1 regulate inflammation in stromal cells from patients with shoulder tendon tears
  73. FRI-109-Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration
  74. Leukocytes from obese individuals exhibit an impaired SPM signature
  75. Novel n-3 Docosapentaneoic Acid-Derived Pro-resolving Mediators Are Vasculoprotective and Mediate the Actions of Statins in Controlling Inflammation
  76. Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1 n −3 DPA
  77. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration
  78. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
  79. n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis
  80. New maresin conjugates in tissue regeneration pathway counters leukotriene D4–stimulated vascular responses
  81. Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology
  82. PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function
  83. Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease
  84. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli–driven acute inflammation
  85. Impaired Production and Diurnal Regulation of Vascular RvD n-3 DPA Increase Systemic Inflammation and Cardiovascular Disease
  86. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults
  87. Endogenously generated arachidonate‐derived ligands for TRPV1 induce cardiac protection in sepsis
  88. Immunoresolvents signaling molecules at intersection between the brain and immune system
  89. Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2
  90. Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis
  91. Performance of Mixed Species and Mono-specific Algal Diets for Culture of Larval Western School Prawns, Metapenaeus dalli
  92. Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections?
  93. Resolvins suppress tumor growth and enhance cancer therapy
  94. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function
  95. The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions
  96. Prolonged immune alteration following resolution of acute inflammation in humans
  97. NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B4 Synthesis
  98. Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy
  99. Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming
  100. Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid
  101. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis
  102. Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide
  103. Protectin D1 n-3 DPA and resolvin D5 n-3 DPA are effectors of intestinal protection
  104. Resolving inflammation by using nutrition therapy
  105. Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes
  106. Immune resolution mechanisms in inflammatory arthritis
  107. Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles
  108. Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTR1 Controls Infection Resolution
  109. Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities
  110. Stereocontrolled synthesis and investigation of the biosynthetic transformations of 16(S),17(S)-epoxy-PDn-3 DPA
  111. Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation
  112. Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators*
  113. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans
  114. Synthesis of 13(R)-Hydroxy-7Z,10Z,13R,14E,16Z,19Z Docosapentaenoic Acid (13R-HDPA) and Its Biosynthetic Conversion to the 13-Series Resolvins
  115. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages
  116. Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue
  117. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation
  118. Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation
  119. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses
  120. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia
  121. Macrophage Proresolving Mediators—the When and Where
  122. Human milk proresolving mediators stimulate resolution of acute inflammation
  123. SPM in CAD and clot remodeling
  124. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis
  125. Lipid mediators and the resolution of chronic inflammation: implications for arthritis therapy
  126. The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation
  127. Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3
  128. Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance
  129. Selective identification of specialized pro-resolving lipid mediators from their biosynthetic double di-oxygenation isomers
  130. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment
  131. Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes
  132. Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins
  133. Synthesis of the 16S,17S-Epoxyprotectin Intermediate in the Biosynthesis of Protectins by Human Macrophages
  134. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages
  135. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment
  136. The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide
  137. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections
  138. Identification of resolvin D2 receptor mediating resolution of infections and organ protection
  139. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function
  140. Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease
  141. A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae
  142. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent
  143. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
  144. Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen
  145. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome
  146. Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways
  147. Cutting Edge: Maresin-1 Engages Regulatory T Cells To Limit Type 2 Innate Lymphoid Cell Activation and Promote Resolution of Lung Inflammation
  148. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1
  149. Proresolving Nanomedicines Activate Bone Regeneration in Periodontitis
  150. Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective
  151. Lipid Mediators in the Resolution of Inflammation
  152. Correction: Corrigendum: Novel n-3 Immunoresolvents: Structures and Actions
  153. Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection
  154. Plasma Metabolomics in Human Pulmonary Tuberculosis Disease: A Pilot Study
  155. Aging Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines
  156. Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1n−3 DPAUtilizing an sp3-sp3Negishi Cross-Coupling Reaction
  157. Synthesis and Anti-inflammatory and Pro-resolving Activities of 22-OH-PD1, a Monohydroxylated Metabolite of Protectin D1
  158. Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1n−3 DPAUtilizing an sp3-sp3Negishi Cross-Coupling Reaction
  159. Maresin Biosynthesis and Identification of Maresin 2, a New Anti-Inflammatory and Pro-Resolving Mediator from Human Macrophages
  160. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue
  161. Cutting Edge: Parathyroid Hormone Facilitates Macrophage Efferocytosis in Bone Marrow via Proresolving Mediators Resolvin D1 and Resolvin D2
  162. Vagus nerve controls resolution and pro-resolving mediators of inflammation
  163. Total Synthesis of the Lipid Mediator PD1n-3 DPA: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions
  164. Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression
  165. Stereoselective synthesis of protectin D1: a potent anti-inflammatory and proresolving lipid mediator
  166. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis
  167. Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators
  168. Contributions of the Three CYP1 Monooxygenases to Pro-Inflammatory and Inflammation-Resolution Lipid Mediator Pathways
  169. Microparticles are novel effectors of immunity
  170. Heterogeneity in Neutrophil Microparticles Reveals Distinct Proteome and Functional Properties
  171. Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Unique Proresolving Mediator–Heme Oxygenase-1 Circuits
  172. Proresolving and Tissue-Protective Actions of Annexin A1–Based Cleavage-Resistant Peptides Are Mediated by Formyl Peptide Receptor 2/Lipoxin A4 Receptor
  173. Novel n-3 Immunoresolvents: Structures and Actions
  174. The novel 13 S ,14 S ‐epoxy‐maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A 4 hydrolase (LTA 4 H), and shifts macropha...
  175. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents
  176. Biphasic Modulation of NOS Expression, Protein and Nitrite Products by Hydroxocobalamin Underlies Its Protective Effect in Endotoxemic Shock: Downstream Regulation of COX-2, IL-1β, TNF-α, IL-6, and HMGB1 Expression
  177. Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors
  178. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions
  179. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC–MS/MS
  180. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators
  181. Self-Limited versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA
  182. Genetic Ablation of the Fpr1 Gene Confers Protection from Smoking-Induced Lung Emphysema in Mice
  183. Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat
  184. Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci
  185. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages
  186. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain
  187. Annexin A1 N-Terminal Derived Peptide Ac2-26 Exerts Chemokinetic Effects on Human Neutrophils
  188. Annexin A1 regulates neutrophil clearance by macrophages in the mouse bone marrow
  189. Evidence for an Anti-Inflammatory Loop Centered on Polymorphonuclear Leukocyte Formyl Peptide Receptor 2/Lipoxin A4 Receptor and Operative in the Inflamed Microvasculature
  190. Corrections: Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
  191. 561 THE CINOD NCX 429 INHIBITS MICROVASCULAR INFLAMMATION THROUGH ITS NO-RELEASING PROPERTIES
  192. Downstream Gene Activation of the Receptor ALX by the Agonist Annexin A1
  193. Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature
  194. CFTR Inhibition Provokes an Inflammatory Response Associated with an Imbalance of the Annexin A1 Pathway
  195. FPR2/ALX receptor expression and internalization are critical for lipoxin A4and annexin‐derived peptide‐stimulated phagocytosis
  196. Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
  197. Exploiting the Annexin A1 pathway for the development of novel anti‐inflammatory therapeutics
  198. Functional and Ultrastructural Analysis of Annexin A1 and Its Receptor in Extravasating Neutrophils during Acute Inflammation
  199. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles
  200. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation